IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02055979.html

The Single Market in Pharmaceuticals

Author

Listed:
  • Margaret Kyle

    (CERNA i3 - Centre d'économie industrielle i3 - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique)

Abstract

This paper examines the state of the single market in the European Union (EU) for pharmaceuticals. As with other products, the EU has adopted a number of institutions and policies to encourage integration and the free movement of goods. Over time, member states are more similar in the availability of pharmaceutical products, as well as in the patents that protect them. New pharmaceuticals are generally available sooner and in more EU members. However, there are large differences in the number and mix of products across member states. Because the pricing of pharmaceuticals remains a national competence, price variation also persists—though this may be desirable from a social welfare standpoint.
(This abstract was borrowed from another version of this item.)

Suggested Citation

  • Margaret Kyle, 2019. "The Single Market in Pharmaceuticals," Post-Print hal-02055979, HAL.
    • Handle: RePEc:hal:journl:hal-02055979
    DOI: 10.1007/s11151-019-09694-6
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a
    for a similarly titled item that would be available.

    Other versions of this item:

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. is not listed on IDEAS
    2. Laura Birg, 2024. "The design of external reference pricing schemes and the choice of reference countries and pricing rules," Canadian Journal of Economics/Revue canadienne d'économique, John Wiley & Sons, vol. 57(4), pages 1182-1202, November.
    3. Fabian Grünwald & Tom Stargardt, 2024. "Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market," Health Economics, John Wiley & Sons, Ltd., vol. 33(7), pages 1546-1564, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02055979. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.